article thumbnail

ASBM Comments on FDA Draft Guidance Removing Interchangeability Statement from Interchangeable Biosimilars

Safe Biologics

The guidance removed the interchangeability statement from the product label/package insert of interchangeable biosimilars. state law, only interchangeable biosimilars may be substituted by a pharmacist without contacting the prescriber.

article thumbnail

November 2023 Newsletter

Safe Biologics

ASBM and GaBI Webinar Examines Policy Challenges to Interchangeable Biosimilars On November 30, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted I nterchangeable Designation for Biosimilars- Ensuring Continuity of Patient Care: Upholding Interchangeability Status for Biosimilars.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

September 2023 Newsletter

Safe Biologics

6 “The Biosimilar Red Tape Elimination Act”, which would prevent the HHS Secretary from requiring switching studies in order for a biosimilar to be deemed “interchangeable” Under U.S. state law, only biosimilars which are interchangeable may be substituted by a pharmacist without contacting the prescriber.

article thumbnail

October 2023 Newsletter

Safe Biologics

prescribers have high confidence in the safety and efficacy of biosimilars, a majority (58%) oppose third-party switching of a patient’s biologic medicine for non-medical (e.g. state law, only biosimilars which are interchangeable may be substituted by a pharmacist without contacting the prescriber. and worldwide.”

article thumbnail

FDA Denies Vanda’s Citizen Petitions Regarding the Need for Braille Labeling for Tasimelteon Generics

FDA Law Blog: Biosimilars

Vanda requested that FDA revoke the approval of Apotex’s and Teva’s generic versions of Hetlioz on the grounds that the generic tasimelteon products did not meet the statutory “same labeling” requirement for generic drugs found in 21 U.S.C. § Vanda’s Hetlioz was, in fact, the first FDA-approved drug product to include braille labeling.

article thumbnail

Health Canada’s proposed amendments to the Food and Drug Regulations and the Medical Devices Regulations

Pharma in Brief

Generic drugs and biosimilars are not eligible for this application pathway. The amendments contemplate labelling flexibilities for special containers. Further, a statement indicating the approved storage conditions and appropriate safety statements for a biologic could be required on certain labels. Biologic Drugs.

article thumbnail

Animals Need Drugs Too, But Not Without CVM Approval

FDA Law Blog: Biosimilars

Specifically, CVM ensures that animal drugs are safe and effective, properly made, and adequately labeled and packaged; food-producing animals only take drugs that would be safe for humans to consume; pet foods and additives are safe; and educates the public, monitors the market, and encourages development of new animal health products.